1. Generics Bulletin
  2. >>Legal & IP

AAM Steps Into GSK-Teva Case To Defend Carve-Outs

Ruling On Skinny Labels Must Not Become ‘Road Map’ For Originators

 
• By Dave Wallace

The AAM has stepped into controversial litigation between Teva and GSK over generic labelling carve-outs, urging the US Court of Appeals for the Federal Circuit to rehear the case to prevent the rules on so-called skinny labels from being subverted.

Chisel carve stone
Generics firms must be able to carve out indications, the AAM says • Source: Shutterstock

A controversial ruling by the US Court of Appeals for the Federal Circuit over generic labeling carve-outs should be reheard “en banc” by the full court, to correct a misinterpretation of the rules around so-called skinny labels, the Association for Accessible Medicines has urged in an amicus brief.

The case involving GlaxoSmithKline and Teva over Coreg (carvedilol) made waves earlier this year when a split appeals court decision...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

‘Prescription Drugs Are Not Golf Balls’ – Opinions Clash On Patents During FTC/DOJ Listening Session

 
• By Urtė Fultinavičiūtė

Pro-innovator voices argued that the number of patents asserted in the pharma industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

Zydus Trastuzumab Suit Dismissed In India For ‘Illusion Of Cause Of Action’

 
• By Dean Rudge

After nearly a decade of procedural delays, a Bombay High Court has finally tossed Zydus Cadila’s pre-emptive complaint against Roche over its Herceptin biosimilar, calling it an “illusion” of a real dispute.

Alchem Fined Over Buscopan API Cartel

 
• By Dave Wallace

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By Dave Wallace

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

More from Generics Bulletin

Zydus Trastuzumab Suit Dismissed In India For ‘Illusion Of Cause Of Action’

 
• By Dean Rudge

After nearly a decade of procedural delays, a Bombay High Court has finally tossed Zydus Cadila’s pre-emptive complaint against Roche over its Herceptin biosimilar, calling it an “illusion” of a real dispute.

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Collating data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

Alchem Fined Over Buscopan API Cartel

 
• By Dave Wallace

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.